GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Current Liabilities | ₹5,819 Cr | ₹4,546 Cr | ₹4,689 Cr | ₹4,201 Cr | ₹4,126 Cr |
What is the latest Total Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
Year | Total Current Liabilities |
---|---|
Mar2024 | ₹5,819 Cr |
Mar2023 | ₹4,546 Cr |
Mar2022 | ₹4,689 Cr |
Mar2021 | ₹4,201 Cr |
Mar2020 | ₹4,126 Cr |
How is Total Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
Years | Total Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹5,819 Cr | 27.99 | |
Mar2023 | ₹4,546 Cr | -3.05 | |
Mar2022 | ₹4,689 Cr | 11.63 | |
Mar2021 | ₹4,201 Cr | 1.82 | |
Mar2020 | ₹4,126 Cr | - |
Compare Total Current Liabilities of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹60,869.1 Cr | 0.9% | 23% | 49.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹410,466.0 Cr | 1.7% | 2% | -0.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹177,298.0 Cr | 0.4% | -2% | 37.3% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹127,538.0 Cr | 6% | 10.5% | 13.6% | Stock Analytics | |
CIPLA | ₹127,140.0 Cr | 6.8% | 4.6% | -0.5% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹108,500.0 Cr | 4.2% | 1.3% | -6.7% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | 0.9% |
23% |
49.1% |
SENSEX | -1% |
-3.2% |
1.6% |
You may also like the below Video Courses